Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lück

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Deutsche Medizinische Wochenschrift (1946)|March 19, 1982
[Mitral valve prolapse and platelet activity in young patients with cerebral ischaemia (author's transl)]V Bluschke, M Hennerici, R E Scharf, et al.
Seminars in Oncology|November 28, 1997
Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancerH J Lück, C Thomssen, A du Bois, et al.
Oncology (Williston Park, N.Y.)|April 1, 1997
Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancerH J Lück, A Du Bois, C Thomssen, et al.
Oncology (Williston Park, N.Y.)|March 28, 1998
Metastatic breast cancer: experience with the combination paclitaxel plus epirubicinH J Lück, C Thomssen, A Du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1997
Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancerA du Bois, H J Lück, T Bauknecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupA du Bois, H J Lück, T Bauknecht, et al.
International Journal of Cancer|August 5, 2000
Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 geneI Sturm, S Papadopoulos, T Hillebrand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2013
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancerP Hadji, M Blettner, N Harbeck, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 14, 1999
Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapyA du Bois, M Schlaich, H J Lück, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2001
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study GroupA du Bois, H J Lück, J Pfisterer, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Deutsche Medizinische Wochenschrift (1946)|March 19, 1982
[Mitral valve prolapse and platelet activity in young patients with cerebral ischaemia (author's transl)]V Bluschke, M Hennerici, R E Scharf, et al.
Seminars in Oncology|November 28, 1997
Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancerH J Lück, C Thomssen, A du Bois, et al.
Oncology (Williston Park, N.Y.)|April 1, 1997
Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancerH J Lück, A Du Bois, C Thomssen, et al.
Oncology (Williston Park, N.Y.)|March 28, 1998
Metastatic breast cancer: experience with the combination paclitaxel plus epirubicinH J Lück, C Thomssen, A Du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1997
Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancerA du Bois, H J Lück, T Bauknecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupA du Bois, H J Lück, T Bauknecht, et al.
International Journal of Cancer|August 5, 2000
Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 geneI Sturm, S Papadopoulos, T Hillebrand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2013
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancerP Hadji, M Blettner, N Harbeck, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 14, 1999
Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapyA du Bois, M Schlaich, H J Lück, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2001
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study GroupA du Bois, H J Lück, J Pfisterer, et al.
Pageof 5